Point mutations in CBL were highly enriched in patients with NF1-mutated tumours, showing a trend (p = 0.18) towards worse OS.<h4>Conclusions</h4>Our findings suggest CBL as a novel driver gene in melanoma, which is mutated in a relevant fraction of patients. This evidence concerns the gene NF1 and melanoma.